Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
67.00
Ask:
70.00
Spread: 3.00 (4.478%)
Market Cap: £60.33m
CLX Live PriceLast checked at - London Stock Exchange

Intraday Calnex Solutio. Share Chart

AGM Statement

19 Aug 2021 07:00

RNS Number : 0241J
Calnex Solutions PLC
19 August 2021
 

19 August 2021

 

Calnex Solutions plc

("Calnex", the "Company" or the "Group")

 

AGM Statement

Calnex Solutions plc, an established provider of test and measurement solutions for the global telecommunications sector, is pleased to provide an update on trading ahead of its Annual General Meeting taking place at 9am today.

 

Calnex has continued to achieve strong trading and good order levels in the first quarter of FY22, in line with the Board's expectations. Of note in the first few months of the year has been a positive response to the Group's enhancements to its Lab Sync platform, Paragon-Neo, with customers placing encouraging levels of pre-orders ahead of launch later in the year. This new functionality will support testing on the very high speed 400G interface and the new PAM4 interface format. This is a key technology development which is expected to be widely adopted, as organisations upgrade their network infrastructure to cope with the increasing amount of data as a result of the increase in cloud computing and evolution to 5G. Additional recent product developments include the enhancement of our Field Sync platform with, what the Board believes is, the unique ability to test 5G Networks alongside the 3G and 4G support already available, increasing the attractiveness of the platform as telecoms operators look to maintaining their new 5G networks. Whilst cognisant of the uncertainty in the wider industry over the ongoing global semiconductor shortage, the Group has not experienced any negative impact on the ability to manufacture and ship product to date, and the Board continues to monitor the situation closely.

 

The Company was also pleased to receive a Gold standard accreditation from Investors in People, reflecting recognition of Calnex as an organisation with the very best in people management excellence.

 

The strength of trading and positive evolutionary trends affecting the telecoms sector described above provide the Board with continued confidence in Calnex's ability to deliver on its growth strategy and a positive outcome to the year in line with current market expectations.

 

For more information, please contact:

 

Calnex Solutions plc

Via Alma PR

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

 

 

 

Cenkos Securities plc - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

 

 

 

Alma PR

+ 44(0) 20 3405 0213

Caroline Forde, Harriet Jackson, Joe Pederzolli

 

 

 

Overview of Calnex

 

Calnex designs, produces and markets test instrumentation and solutions for network synchronization and network emulation, enabling its customers to validate the performance of the critical infrastructure associated with telecoms networks. To date, Calnex has secured and delivered orders to over 600 customer sites in 68 countries across the world. Customers include BT, China Mobile, NTT, Ericsson, Nokia, Intel, Qualcomm, IBM and Facebook.

 

Founded in 2006, Calnex is headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland and California in the US, supported by sales teams in China and India. Calnex has a global network of partners, providing a worldwide distribution capability. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMSFWSAAEFSEFA
Date   Source Headline
11th Apr 200710:41 amRNSRule 38 Calyx Group plc
5th Apr 20079:15 amRNSNotice of Results
15th Mar 20072:26 pmRNSRule 8.3- Calyx Group plc
15th Mar 200710:30 amRNSRule 8.1 Calyx Group plc
13th Mar 20073:15 pmRNSShare Price Movement
8th Feb 20072:33 pmRNSIssue of Equity
27th Dec 20067:00 amRNSIEX Notice
22nd Dec 200611:25 amRNSTotal Voting Rights
19th Dec 20063:46 pmRNSIssue of Shares
15th Dec 20067:58 amRNSShare disposal
14th Dec 20065:08 pmRNSHolding(s) in Company
12th Dec 20068:48 amRNSChange to earn outs
12th Dec 20068:00 amRNSAcquisition & Trading Update
1st Nov 20067:00 amRNSShare Options
25th Sep 20067:03 amRNSInterim Results
27th Jul 20067:00 amRNSDirectorate Change
6th Jul 20067:00 amRNSIEX Notice
30th Jun 20063:58 pmRNSIssue of Equity
29th Jun 20067:01 amRNSAppt of Non-Exec Directors
12th Jun 200612:37 pmRNSNew IEX Admission
12th Jun 20068:00 amRNSAcquisitions & Placing
12th Jun 20067:00 amRNSIEX Notice
9th Jun 200611:45 amRNSResult of AGM and EGM
7th Jun 20068:47 amRNSSch 1 Update - Calyx Group
22nd May 20063:15 pmRNSIEX Schedule One
19th May 20068:56 amRNSSch 1 - Calyx Group
17th May 20067:02 amRNSDisposal
17th May 20067:02 amRNSAcquisition,Admission,Placing
6th Mar 20067:02 amRNSFinal Results
1st Mar 20062:02 pmRNSAcquisition
19th Jan 20067:01 amRNSBT Agreement
26th Oct 20057:00 amRNSUK Acquisition
20th Oct 20054:08 pmRNSAcquisition
30th Aug 20057:02 amRNSMaiden Interim Results
11th Jul 20057:00 amRNSAcquisition & Trading Update
9th Jun 20053:16 pmRNSDirector Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.